<DOC>
	<DOCNO>NCT02401464</DOCNO>
	<brief_summary>The purpose study evaluate bioequivalence single oral dose 2 different drug form TAK-536 pediatric formulation single oral dose TAK-536 commercial tablet healthy Japanese adult male participant .</brief_summary>
	<brief_title>A Bioequivalence Study TAK-536 Pediatric Formulation</brief_title>
	<detailed_description>This study design evaluate bioequivalence single oral dose 2 different drug form TAK-536 pediatric formulation ( dry syrup , granule ) single oral dose TAK-536 commercial tablet use open-label , 2 Ã— 2 crossover design .</detailed_description>
	<criteria>1 . In opinion investigator subinvestigator , participant capable understand comply protocol requirement . 2 . The participant sign date write , informed consent form ( ICF ) require privacy authorization prior initiation study procedure . 3 . The participant healthy Japanese adult male volunteer . 4 . The participant 20 35 year age time informed consent . 5 . The participant body weight least 50.0 kilogram ( kg ) body mass index ( BMI ) 18.5 25.0 kilogram per meter square ( kg/m^2 ) time screen . 1 . The participant show symptom dizziness standing , facial pallor , cold sweat , etc , suspect hypotension medical examination/physical finding screen day administration study drug Period 1 , administration study drug Period 1 . 2 . The participant receive investigational compound within 16 week ( 112 day ) prior start study medication Period 1 3 . The participant receive TAK536 TAK491 previous clinical study therapeutic agent . 4 . The participant uncontrolled , clinically significant neurologic , cardiovascular , pulmonary , hepatic , renal , metabolic , gastrointestinal , urologic endocrine disease abnormality may impact ability participant participate potentially confound study result . 5 . The participant know hypersensitivity TAK536 angiotensin II receptor blocker . 6 . The participant positive result urine drug screen test screening . 7 . The participant history drug abuse ( define illicit drug use ) history alcohol abuse within 2 year prior screen unwilling agree abstain alcohol drug throughout study period . 8 . The participant take excluded medication , supplement , food product time period . 9 . The participant current recent ( within 6 month ) gastrointestinal disease would expect influence absorption drug ( ie , history malabsorption , esophageal reflux , peptic ulcer disease , erosive esophagitis , frequent [ per week ] occurrence heartburn , surgical intervention ( ie , cholecystectomy ) . 10 . The participant history cancer . 11 . The participant positive test result hepatitis B surface antigen ( HBsAg ) , hepatitis C virus ( HCV ) antibody , human immunodeficiency virus ( HIV ) antibody/antigen , serological reaction syphilis screen . 12 . The participant poor peripheral venous access . 13 . The participant undergone whole blood collection least 200 mL within 4 week ( 28 day ) least 400 mL within 12 week ( 84 day ) prior start study medication administration Period 1 . 14 . The participant undergone whole blood collection least 800 mL total within 52 week ( 364 day ) prior start study medication administration Period 1 . 15 . The participant undergone blood component collection within 2 week ( 14 day ) prior start study medication administration Period 1 . 16 . The participant abnormal ( clinically significant ) electrocardiogram screen prior start study medication Period 1 . 17 . The participant abnormal laboratory value screen prior start study medication Period 1 suggest clinically significant underlying disease participant follow lab abnormality : alanine transaminase ( ALT ) aspartate transaminase ( AST ) great ( &gt; ) 1.5 time upper limit normal . 18 . The participant , opinion investigator subinvestigator , unlikely comply protocol unsuitable reason .</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>